Better Health for All

Werewolf Therapeutics' entire business is dedicated to developing novel therapies for cancer and immune-mediated conditions, with 100% of its pipeline focused on these areas. Clinical trials for WTX-124 have shown objective responses, including one durable confirmed complete remission in a patient with advanced skin cancer, demonstrating exceptional potential health benefits.

As a pre-revenue company, it generates no revenue from commercial products, and therefore has zero revenue from products with negative health outcomes. The safety record for WTX-124 in clinical trials is strong, with all reported adverse events being mild to moderate (Grade 1 or 2), and no dose-limiting toxicities, serious adverse events, or treatment discontinuations due to toxicity observed across 47 heavily pretreated patients. The company's R&D expenses were $13.1 million in Q1 2025, an increase from $12.9 million in Q1 2024. While a skin cancer awareness campaign was launched in May, there is no specific data on its reach or impact to score healthcare education. There is no specific information regarding the ethical conduct of clinical trials beyond the reporting of safety data.

Fair Money & Economic Opportunity

Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on cancer treatment.

The company does not offer financial products or services such as lending, deposits, or insurance to consumers. Therefore, all Key Performance Indicators (KPIs) related to fair money and economic opportunity, which are designed to assess financial institutions, are not applicable to its business operations.

Fair Pay & Worker Respect

No specific, concrete data points were found in the provided articles to assess Werewolf Therapeutics, Inc. against any of the KPIs for Fair Pay & Worker Respect. Information regarding living wage coverage, CEO-to-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, voluntary turnover rate, insecure contract share, and health insurance coverage was not available.

While one article mentioned a wage and hour putative class and Private Attorneys General Act (PAGA) action, it did not state that any violations were substantiated against Werewolf Therapeutics, Inc. The company had 46 employees as of June 30, 2025, and 39 employees as of September 30, 2025.

Kind to Animals

The company uses animal models in preclinical studies for drug development, including mouse models for colitis and to monitor pharmacology.

All mouse in vivo work is performed in accordance with U.S. Department of Health and Human Services, Public Health Service, NIH Office of Laboratory Animal Welfare, and U.S. Department of Agriculture regulations, with approval from Institutional Animal Care and Use Committees (IACUC) at Charles River Laboratories. The company explicitly states its use of animals for testing in a report. Research and development expenses were $12.5 million for the third quarter of 2024, compared to $10.8 million for the same period in 2023, but there is no specific percentage of this budget allocated to animal-free technologies.

No War, No Weapons

No specific, factual evidence was found in the provided articles to assess Werewolf Therapeutics, Inc. against any of the 'No War, No Weapons' KPIs. The company description outlines its focus on biopharmaceuticals for cancer treatment, but this is not a scorable data point for the given KPIs, which require explicit facts about revenue, policies, or actions related to arms, defense, or peacebuilding. One article mentioned an SDG Transparency Score, but this is not relevant to the specific metrics for this value.

The other article was inaccessible.

Respect for Cultures & Communities

No evidence was found in the provided article to assess Werewolf Therapeutics, Inc. against the 'Respect for Cultures & Communities' value.

The article details governance documents such such as the Board of Directors' responsibilities, Code of Business Conduct and Ethics, Corporate Governance Guidelines, and Committee Charters, but contains no specific data points related to community engagement, cultural impact, local investment, or any other relevant metrics for this value.

Safe & Smart Tech

The company conducts cybersecurity training and testing for all employees, covering topics such as social engineering, phishing, password protection, confidential data protection, and mobile security, and educates them on reporting incidents immediately.

Employees, officers, and directors must also certify annually their compliance with the Code of Business Conduct and Ethics. Users can contact the company to stop receiving communications or have their personally identifiable information deleted, with exceptions for adverse drug event information or data required to be retained by law. The company engages third-party consultants to conduct penetration testing and vulnerability assessments. It states that users may visit its website without providing any personal information. The company requires all employees, officers, and directors to comply with all applicable laws, rules, and regulations, including the Foreign Corrupt Practices Act, and permits communication with government agencies regarding legal violations. The company's Director of Operations, along with leaders from operations, finance, and legal departments, are responsible for documenting, reviewing, and assessing cybersecurity processes, monitoring for incidents, and periodically reporting on cybersecurity risks to the audit committee.